Literature DB >> 25447803

Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.

Matteo Bassetti1, Giovanni Villa, Filippo Ansaldi, Daniela De Florentiis, Carlo Tascini, Piergiogio Cojutti, Elda Righi, Assunta Sartor, Massimo Crapis, Francesco Giuseppe De Rosa, Federico Pea, Francesco Menichetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25447803     DOI： 10.1007/s00134-014-3571-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Nadia Z Haque; Mary Beth Perri; Susan Donabedian; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

2.  High-dose daptomycin in documented Staphylococcus aureus infections.

Authors:  Matteo Bassetti; Elena Nicco; Francesca Ginocchio; Filippo Ansaldi; Daniela de Florentiis; Claudio Viscoli
Journal:  Int J Antimicrob Agents       Date:  2010-09-16       Impact factor: 5.283

3.  Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Marco Falcone; Alessandro Russo; Mario Venditti; Andrea Novelli; Manjunath P Pai
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

Review 4.  Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.

Authors:  Pamela A Moise; Donald North; Judith N Steenbergen; George Sakoulas
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

5.  High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia.

Authors:  M Sharma; K Riederer; P Chase; R Khatib
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267
  5 in total
  5 in total

1.  Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience.

Authors:  Matteo Bassetti; Filippo Ansaldi; Daniela De Florentiis; Elda Righi; Federico Pea; Assunta Sartor; Claudio Scarparo; Alessia Carnelutti
Journal:  Intensive Care Med       Date:  2015-08-20       Impact factor: 17.440

Review 2.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

3.  In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.

Authors:  A Capone; V Cafiso; F Campanile; G Parisi; B Mariani; N Petrosillo; S Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-27       Impact factor: 3.267

4.  Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection.

Authors:  Yu-Jui Chang; Mel S Lee; Chen-Hsiang Lee; Po-Chun Lin; Feng-Chih Kuo
Journal:  BMC Infect Dis       Date:  2017-11-29       Impact factor: 3.090

5.  Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost.

Authors:  Melanie Roch; Paula Gagetti; James Davis; Paola Ceriana; Laura Errecalde; Alejandra Corso; Adriana E Rosato
Journal:  Front Microbiol       Date:  2017-12-05       Impact factor: 5.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.